PMA device
Essure System
Bayer Pharma AG · Transcervical Contraceptive Tubal Occlusion Device (HHS, Class III) · First FDA decision Nov 4, 2002, newest Nov 15, 2016Contraception
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
14
PMA pathway
Device trials
15
Naming "Essure"
MAUDE reports
70,898
Brand "Essure", since 2015
PubMed studies
373
Mentioning "Essure"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Essure System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 14 decisions filed under this name.
- ESSURE SYSTEMPMA supplement
P020014-S046 · Decided Nov 15, 2016 · 180 days after receipt · Normal 180 Day Track
Device type: Transcervical contraceptive tubal occlusion device (HHS) · Obstetrics & Gynecology
- Essure System for Permanent Birth Control (Model ESS305)PMA supplement
P020014-S047 · Decided Sep 29, 2016 · 62 days after receipt · Normal 180 Day Track No User Fee
Device type: Transcervical contraceptive tubal occlusion device (HHS) · Obstetrics & Gynecology
- ESSURE SYSTEMPMA supplement
P020014-S045 · Decided Apr 28, 2016 · 63 days after receipt · Normal 180 Day Track No User Fee
Device type: Transcervical contraceptive tubal occlusion device (HHS) · Obstetrics & Gynecology
3 more FDA decisions with a free account
Older decisions: P020014-S041, P020014-S039, P020014-S026, P020014-S019, P020014-S009, P020014-S006, P020014-S005, P020014
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Ambulatory Blood Pressure Monitoring (ABPM)National analysisReview closedCAG-00067R2Updated Nov 19, 2026
- Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD)National determinationOn the books240.9Updated Oct 26, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure consequent to COPDNational analysisReview closedCAG-00465NUpdated Sep 18, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
- Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)National analysisReview closedCAG-00093R2Updated Sep 17, 2026
- Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)National analysisReview closedCAG-00093RUpdated Sep 17, 2026
- Noninvasive Positive Pressure RADs for COPDNational analysisReview closedCAG-00052NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Essure", any status and sponsor, newest update first.
BayerNot on our public-company list
NCT03127722 · 990 participants · Start May 3, 2017 · Primary completion Dec 31, 2024
Device: ESSURE (BAY1454032) · For: Contraception
Sites: Chandler, Arizona; Phoenix, Arizona; Tucson, Arizona · 57 sites in all
Hospices Civils de LyonAcademic, hospital or other
NCT06355713 · 444 participants (planned) · Start Feb 17, 2025 · Primary completion Apr 17, 2032
Device: Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination · For: Implant Complication; Contraceptive Device; Complications
Sites: Angers, France; Bron, France; Le Kremlin-Bicêtre, France · 10 sites in all
Wright State UniversityAcademic, hospital or other
NCT02628873 · 21 participants · Start Dec 2015 · Primary completion Sep 2018
Device: HyCoSy · For: Contraception
Sites: Dayton, Ohio
12 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Essure", and for the whole product code for context.
This brand
70,898 reports: 740 malfunction, 69,984 injury, 128 death
Whole product code HHS
70,887 reports: 735 malfunction, 69,978 injury, 128 death
Newest reports for this brand
- ESSUREInjury
2951250-2026-00333 · Received Oct 29, 2026
Device type: Transcervical Contraceptive Tubal Occlusion Device (HHS)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Pelvic Pain
- ESSUREInjury
2951250-2026-00334 · Received Oct 29, 2026
Device type: Transcervical Contraceptive Tubal Occlusion Device (HHS)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Pelvic Pain
- ESSUREInjury
2951250-2026-00335 · Received Oct 29, 2026
Device type: Transcervical Contraceptive Tubal Occlusion Device (HHS)
Device problem as coded: Adverse Event Without Identified Device or Use Problem; Patient Device Interaction Problem
Patient problem as coded: Abdominal Pain; Headache; Menstrual Irregularities; Unspecified Reproductive System or Breast Problem; Pelvic Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Essure"[tiab]. The summary above synthesizes these.
- Transcervical sterilization.
Castaño PM, Adekunle L · Semin Reprod Med · 2010Review
- Removal of Essure: TMTOWTDI.
Bhagavath B, Lindheim S · Fertil Steril · 2020Editorial, Comment
- [Essure® implants: What's news in the management of symptomatic patients?].
Chene G, Graesslin O · Gynecol Obstet Fertil Senol · 2022Editorial
- "Fibromyalgia syndrome" related to Essure devices.
Dernoncourt A, Serpier M, Gagneur O, et al. · Autoimmun Rev · 2022Letter
- Essure: hysteroscopic sterilization.
Hastings-Tolsma M, Nodine P, Teal SB · J Midwifery Womens Health · 2006Case Reports, Review
- Analysis of explanted Essure® devices.
Christ L, Boisramé T, Neumann N, et al. · Eur J Obstet Gynecol Reprod Biol · 2025
- Essure treatment of hydrosalpinges.
Hitkari JA, Singh SS, Shapiro HM, et al. · Fertil Steril · 2007Case Reports, Evaluation Study
- Clinical improvement after Essure® devices removal: a systematic review.
Miguet-Bensouda C, Parant F, Grenet G, et al. · Eur J Contracept Reprod Health Care · 2023Systematic Review
- Hysteroscopic tubal sterilization.
Magos A, Chapman L · Obstet Gynecol Clin North Am · 2004Review
- Essure removal surgery: Are preoperative transvaginal ultrasound and pelvic X-ray necessary?
van Erp MAJM, Maassen LW, van Gastel DM, et al. · Eur J Obstet Gynecol Reprod Biol · 2023
- Symptomatic Bilateral Granulomas after Essure Sterilization.
Hoogendam JP, Vreuls CPH, Veersema S · J Minim Invasive Gynecol · 2020
- Dislodged Essure microinsert.
Booker CJ, Yarwood RL, Dodson WC · Fertil Steril · 2008Case Reports
Other devices of this type
Also filed under product code HHS.
- Conceptus Essure SystemBayer Pharma AG · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.